Biotech entity
Every one of those 1 sits in a single category, clinical-trial. NaV 1.8 inhibitor is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 2.4 for the broader beat in this window.
Last mentioned: Feb 19, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, clinical-trial. NaV 1.8 inhibitor is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 2.4 for the broader beat in this window. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window. We currently track 1 Biotech story that mention Grünenthal Group, all published on February 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 27 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Grünenthal Group. Shared-story counts are live from our verified record — not editorial picks.
Grünenthal has initiated clinical development for its proprietary NaV 1.8 inhibitor, a highly selective non-opioid analgesic candidate. This milestone positions the German pain specialist as a key contender in the race to develop potent, non-addictive treatments for acute and chronic pain.
Grünenthal Group is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
